JP2004521095A5 - - Google Patents

Download PDF

Info

Publication number
JP2004521095A5
JP2004521095A5 JP2002549637A JP2002549637A JP2004521095A5 JP 2004521095 A5 JP2004521095 A5 JP 2004521095A5 JP 2002549637 A JP2002549637 A JP 2002549637A JP 2002549637 A JP2002549637 A JP 2002549637A JP 2004521095 A5 JP2004521095 A5 JP 2004521095A5
Authority
JP
Japan
Prior art keywords
isoindol
dihydro
oxo
propionamide
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002549637A
Other languages
English (en)
Japanese (ja)
Other versions
JP4021766B2 (ja
JP2004521095A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/014404 external-priority patent/WO2002048106A2/en
Publication of JP2004521095A publication Critical patent/JP2004521095A/ja
Publication of JP2004521095A5 publication Critical patent/JP2004521095A5/ja
Application granted granted Critical
Publication of JP4021766B2 publication Critical patent/JP4021766B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002549637A 2000-12-13 2001-12-07 イソインドリン−1−オンのグルコキナーゼアクチベーター Expired - Fee Related JP4021766B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (3)

Publication Number Publication Date
JP2004521095A JP2004521095A (ja) 2004-07-15
JP2004521095A5 true JP2004521095A5 (cg-RX-API-DMAC10.html) 2005-05-26
JP4021766B2 JP4021766B2 (ja) 2007-12-12

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002549637A Expired - Fee Related JP4021766B2 (ja) 2000-12-13 2001-12-07 イソインドリン−1−オンのグルコキナーゼアクチベーター

Country Status (35)

Country Link
US (1) US6482951B2 (cg-RX-API-DMAC10.html)
EP (1) EP1349856B1 (cg-RX-API-DMAC10.html)
JP (1) JP4021766B2 (cg-RX-API-DMAC10.html)
KR (1) KR100520651B1 (cg-RX-API-DMAC10.html)
CN (1) CN1247574C (cg-RX-API-DMAC10.html)
AT (1) ATE297922T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002238415B2 (cg-RX-API-DMAC10.html)
BG (1) BG107903A (cg-RX-API-DMAC10.html)
BR (1) BR0116169A (cg-RX-API-DMAC10.html)
CA (1) CA2430579C (cg-RX-API-DMAC10.html)
CY (1) CY1105587T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20031882A3 (cg-RX-API-DMAC10.html)
DE (1) DE60111570T2 (cg-RX-API-DMAC10.html)
DK (1) DK1349856T3 (cg-RX-API-DMAC10.html)
EG (1) EG24358A (cg-RX-API-DMAC10.html)
ES (1) ES2243578T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20030450B1 (cg-RX-API-DMAC10.html)
HU (1) HUP0400587A3 (cg-RX-API-DMAC10.html)
IL (2) IL156264A0 (cg-RX-API-DMAC10.html)
MA (1) MA26973A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA03005170A (cg-RX-API-DMAC10.html)
MY (1) MY136741A (cg-RX-API-DMAC10.html)
NO (1) NO325810B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ526236A (cg-RX-API-DMAC10.html)
PA (1) PA8534601A1 (cg-RX-API-DMAC10.html)
PE (1) PE20020593A1 (cg-RX-API-DMAC10.html)
PL (1) PL366006A1 (cg-RX-API-DMAC10.html)
PT (1) PT1349856E (cg-RX-API-DMAC10.html)
RS (1) RS50933B (cg-RX-API-DMAC10.html)
RU (1) RU2249590C2 (cg-RX-API-DMAC10.html)
SI (1) SI1349856T1 (cg-RX-API-DMAC10.html)
SK (1) SK8732003A3 (cg-RX-API-DMAC10.html)
TW (1) TWI294876B (cg-RX-API-DMAC10.html)
UY (1) UY27069A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002048106A2 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
DE60316709T2 (de) 2002-10-03 2008-07-17 F. Hoffmann-La Roche Ag Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
RU2412192C2 (ru) 2004-04-02 2011-02-20 Новартис Аг Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
CA2561157A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてglk活性化剤として使用するためのヘテロアリールベンズアミド誘導体
AU2006285834A1 (en) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
JP2009513711A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
WO2009092432A1 (en) * 2008-01-24 2009-07-30 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative
PE20141375A1 (es) * 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
CA2735184C (en) * 2008-09-11 2013-05-28 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
EP3004076B1 (en) * 2013-05-27 2019-10-23 F.Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
CA2224062C (en) * 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
TR200102805T2 (tr) 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri
AU2001252270B2 (en) 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase

Similar Documents

Publication Publication Date Title
JP2004521095A5 (cg-RX-API-DMAC10.html)
CA2430579A1 (en) Isoindolin-1-one glucokinase activators
JP2004506632A5 (cg-RX-API-DMAC10.html)
JP2004504388A5 (cg-RX-API-DMAC10.html)
RU2003120512A (ru) Активаторы изоиндолин-1-он-глюкокиназы
JP2004504301A5 (cg-RX-API-DMAC10.html)
CA2407428A1 (en) Hydantoin-containing glucokinase activators
JP2010520893A5 (cg-RX-API-DMAC10.html)
ES2312051T3 (es) Compuestos que ejercen efecto sobre la glucoquinasa.
JP2005517006A5 (cg-RX-API-DMAC10.html)
CA2482346A1 (en) Substituted phenylacetamides and their use as glucokinase activators
CA2437409A1 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
JP2015535252A5 (cg-RX-API-DMAC10.html)
JP2010538076A5 (cg-RX-API-DMAC10.html)
JP2007530459A5 (cg-RX-API-DMAC10.html)
CA2509086A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
CA2476343A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
JP2010514677A5 (cg-RX-API-DMAC10.html)
JP2012506446A5 (cg-RX-API-DMAC10.html)
RU2008143457A (ru) Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы
JP2005515172A5 (cg-RX-API-DMAC10.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2005526814A5 (cg-RX-API-DMAC10.html)
JP2013505969A5 (cg-RX-API-DMAC10.html)
RU2005121667A (ru) 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы